Bui JD - Search Results

1

Drak2 is not required for tumor surveillance and suppression.

Edwards BA, Harris TL, Floersh H, Lukens JR, Zaki MH, Vogel P, Kanneganti TD, Bui JD, McGargill MA. Edwards BA, et al. Among authors: bui jd. Int Immunol. 2015 Mar;27(3):161-6. doi: 10.1093/intimm/dxu146. Epub 2015 Jan 7. Int Immunol. 2015. PMID: 25568303 Free PMC article.

2

Active Ca2+/calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling.

McGargill MA, Sharp LL, Bui JD, Hedrick SM, Calbo S. McGargill MA, et al. Among authors: bui jd. J Immunol. 2005 Jul 15;175(2):656-64. doi: 10.4049/jimmunol.175.2.656. J Immunol. 2005. PMID: 16002660

3

The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth.

Büchau AS, Morizane S, Trowbridge J, Schauber J, Kotol P, Bui JD, Gallo RL. Büchau AS, et al. Among authors: bui jd. J Immunol. 2010 Jan 1;184(1):369-78. doi: 10.4049/jimmunol.0902110. Epub 2009 Nov 30. J Immunol. 2010. PMID: 19949065 Free PMC article.

4

Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.

Yadav D, Ngolab J, Dang N, Bui JD. Yadav D, et al. Among authors: bui jd. Immunology. 2011 Jun;133(2):197-205. doi: 10.1111/j.1365-2567.2011.03427.x. Epub 2011 Mar 25. Immunology. 2011. PMID: 21438873 Free PMC article.

5

Cancer immunoediting of the NK group 2D ligand H60a.

O'Sullivan T, Dunn GP, Lacoursiere DY, Schreiber RD, Bui JD. O'Sullivan T, et al. Among authors: bui jd. J Immunol. 2011 Oct 1;187(7):3538-45. doi: 10.4049/jimmunol.1100413. Epub 2011 Aug 29. J Immunol. 2011. PMID: 21876033 Free PMC article.

6

The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy.

Peinado C, Kang X, Hardamon C, Arora S, Mah S, Zhang H, Ngolab J, Bui JD. Peinado C, et al. Among authors: bui jd. Immunology. 2013 Jun;139(2):265-74. doi: 10.1111/imm.12080. Immunology. 2013. PMID: 23350962 Free PMC article.

7

IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.

Bui JD, Carayannopoulos LN, Lanier LL, Yokoyama WM, Schreiber RD. Bui JD, et al. J Immunol. 2006 Jan 15;176(2):905-13. doi: 10.4049/jimmunol.176.2.905. J Immunol. 2006. PMID: 16393975

8

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

Bui JD, Schreiber RD. Bui JD, et al. Curr Opin Immunol. 2007 Apr;19(2):203-8. doi: 10.1016/j.coi.2007.02.001. Epub 2007 Feb 9. Curr Opin Immunol. 2007. PMID: 17292599 Review.

9

Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA.

Yadav D, Ngolab J, Lim RS, Krishnamurthy S, Bui JD. Yadav D, et al. Among authors: bui jd. J Immunol. 2009 Jan 1;182(1):39-43. doi: 10.4049/jimmunol.182.1.39. J Immunol. 2009. PMID: 19109132 Free PMC article.

10

Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression.

Zhang H, Hardamon C, Sagoe B, Ngolab J, Bui JD. Zhang H, et al. Among authors: bui jd. Mol Immunol. 2011 Jan;48(4):539-45. doi: 10.1016/j.molimm.2010.10.015. Epub 2010 Nov 19. Mol Immunol. 2011. PMID: 21093919 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

106 results

Search Page